Fintel reports that on November 13, 2024, TD Cowen downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) from ...

Fintel reports that on November 13, 2024, JMP Securities downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) ...

Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from TD Cowen analyst Phil Nadeau yesterday. The ...

Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, ...

TD Cowen analyst Phil Nadeau downgraded Syros Pharmaceuticals (SYRS) to Hold from Buy after the company announced that the SELECT-MDS-1 Phase 3 ...

Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer.

Syros Pharmaceuticals Inc (NASDAQ:SYRS) is advancing tamibarotene as a potential new standard of care for higher-risk MDS patients with RARA overexpression, targeting a significant unmet medical need.

Syros Pharmaceuticals ( (SYRS)) has released its Q3 earnings. Here is a breakdown of the information Syros Pharmaceuticals presented to its investors. Syros Pharmaceuticals, Inc., a ...

Good morning, and welcome to the Syros Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Note that this call is being ...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a biopharmaceutical company focused on developing treatments for cancer and blood disorders, has been navigating a complex landscape of clinical trials ...

Cash and Cash Equivalents: $58.3 million as of September 30, 2024, compared to $79 million as of June 30, 2024. Syros Pharmaceuticals Inc (NASDAQ:SYRS) is advancing tamibarotene as a potential new ...